Pure H20 Bio-Technologies, Inc. Announces Letter of IntentFrom H.M. Northcutt Corporation For Product Installation and Service

BOCA RATON, Fla.--(Business Wire)--
Pure H2O Bio-Technologies, Inc. (Pink Sheets: PRHB) announced today its receipt
of a letter of intent from H.M. Northcutt Corporation, regarding the
installation, monitoring and service of the first 100 Hospital Potable Water
Disinfection Systems, Model 7000 as described below in Pure H20`s Pilot Program.

H.M. Northcutt Corp, located in Mt. Pleasant, South Carolina, is a company with
33 years of experience specializing in sales, installation and service of
innovative water equipment. For additional information visit web-site:
www.hmnorthcutt.com

Upon final National Sanitation Foundation (NSF) certification of Pure H20`s
integrated Hospital Potable Water Disinfection System, Model 7000, the parties
shall enter into a formal agreement detailing the objectives of Pure H20`s Pilot
Program, defining the territories of installation in medical facilities within
the states of Florida, Georgia and the Carolinas, monitoring and determining
replacement and service costs.

In the letter of intent dated May 13, 2009, addressed to Mr. Joseph P. Doxey,
President of Pure H20 Bio-Technologies, Inc., Mr. Charlie Northcutt, President
of H.M. Northcutt Corp stated, "We are proud of our track record in the water
treatment industry. You and your stockholders can rest assured of professional
installation and service through the H.M. Northcutt Corporation.

About Pure H20 Bio-Technologies, Inc.

Pure H2O recently completed its bench, kinetic and pre-certification testing of
its innovative drinking water treatment system with outstanding results. Mr.
Joseph Doxey, President of Pure H2O, stated, "We want to welcome Charlie
Northcutt, H.M. Northcutt Corp., Gary Schmidt, Wes Com Capital and Mike N.
Brette, J.D. of The Wall Street News Hour to our team of accomplished
professionals. I am confident we are building a strong and proven team to
accomplish our goal of bringing our Hospital System to market." The Company was
awarded patent #7250111, and has two additional patents pending at this time
that are under review with the U.S. Patent and Trademark Office, Washington,
D.C.

PILOT PROGRAM: Participant Revenue Sharing Agreement ("PRSA") for its first 100
manufactured Integrated Hospital Potable Water Disinfections System known as
Model 7000.

The Pilot Program is designed to offer an opportunity that benefits all parties
involved. It allows the Company to seek additional capital in the form of
participants sharing revenues generated from intended lease, rental or purchase
agreements; it allows the Company to seek capital through government financial
assistance programs for skilled workers, equipment and expansion. It allows the
commencement of manufacturing the first 100 Hospital Systems; allows expediency
in regard to our micro-team, engineering team, laboratories, government agencies
and officials; it allows a financial opportunity for investors to receive
conservative returns and allows the Company to absorb expenses associated with
NSF Certification without further dilution to shareholders.

Visit our web-site at www.pureh20biotech.com.

The "Participant Revenue Sharing Agreement" ("PRSA") can be viewed on the
Company`s web-site under title "Pilot Program". Further information has been
uploaded for the serious professional including (i) Technical Production Video,
(ii) Written Video Script, (iii) Question & Answers produced by Special Report
T.V. and (iv) Description of the Hospital Potable Water Disinfection System,
Model 7000.

To learn more about our Pilot Program or for additional questions call Mr. Gary
Schmidt at Wescom Capital, Inc. (206) 420-5710 or write to Mr. Schmidt via email
at gls@wescomcapital.com.

The Company will be announcing its progress on a regular basis and will continue
to keep its shareholders apprised through these stages. Visit our web-site for
updates and to view our Pilot Program at www.pureh20biotech.com.

The foregoing press release contains forward-looking statements that can be
identified by such terminology as "expects," "potential," suggests," "may,"
"intends," or similar expressions. Such forward-looking statements involve known
and unknown risks, uncertainties and other factors that may cause the actual
results to be materially different from any future results, performance or
achievements expressed or implied by such statements. In particular,
management's expectations regarding future research, development and/or
commercial results could be affected by, among other things, uncertainties
relating to the availability of future financing; unexpected regulatory delays
or government regulation generally; the company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and completion in
general. Forward-looking statements speak only as to the date they were made.
The company does not undertake to update forward-looking statements to reflect
circumstances or events that occur after the date the forward-looking statements
are made.

Pure H2O Bio-Technologies, Inc., Boca Raton
Elena Canadeo, 561-218-6169

Copyright Business Wire 2009